Arcus Biosciences, Inc. is a clinical-stage biotechnology company focused on developing cancer immunotherapy. The Company has developed drug discovery capability designed to create differentiated small molecules, which has the ability to develop in combinations with its monoclonal antibodies through rationally designed, indication-specific, adaptive clinical trial designs. The Company is focused on creating, developing and commercializing differentiated combination cancer therapies that have the potential to cure. The Company has four clinical-stage investigational products: AB928, AB154, Zimberelimab and AB680.
https://www.arcusbio.com/© 2024 Lime Trading (CY) Ltd
Lime Trading (CY) Ltd is authorised and regulated by the Cyprus Securities and Exchange Commission in accordance with license No.281/15 issued on 25/09/2015. The "Just2Trade" trademark is owned by LimeTrading (CY) Ltd.
Registration Number: HE 341520
Address: Lime Trading (CY) Ltd
Magnum Business Center, Office 4B, Spyrou Kyprianou Avenue 78
Limassol 3076, Cyprus
Disclaimer:
All promotions, materials and information of this website may have applied conditions. Please contact the Company for further details
Trading on financial markets carries risks. The value of the investments can both increase and decrease and the investors may lose all their investment capital. In case of a leveraged product, the loss may be more than the initial capital invested. Detailed information on risks associated with trading on financial markets can be found in General Terms and Conditions for the Provision of Investment Services.
E-mail: 24_support@just2trade.online
